176 related articles for article (PubMed ID: 23136196)
1. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Jameson GS; Hamm JT; Weiss GJ; Alemany C; Anthony S; Basche M; Ramanathan RK; Borad MJ; Tibes R; Cohn A; Hinshaw I; Jotte R; Rosen LS; Hoch U; Eldon MA; Medve R; Schroeder K; White E; Von Hoff DD
Clin Cancer Res; 2013 Jan; 19(1):268-78. PubMed ID: 23136196
[TBL] [Abstract][Full Text] [Related]
2. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Hoch U; Staschen CM; Johnson RK; Eldon MA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
[TBL] [Abstract][Full Text] [Related]
5. Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.
Alemany C
Curr Oncol Rep; 2014 Feb; 16(2):367. PubMed ID: 24445499
[TBL] [Abstract][Full Text] [Related]
6. Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.
Aggarwal C; Cohen RB; Yu E; Hwang WT; Bauml JM; Alley E; Evans TL; Langer CJ
Clin Lung Cancer; 2018 Mar; 19(2):157-162. PubMed ID: 29129435
[TBL] [Abstract][Full Text] [Related]
7. Etirinotecan pegol for the treatment of breast cancer.
López-Miranda E; Cortés J
Expert Opin Pharmacother; 2016; 17(5):727-34. PubMed ID: 26881332
[TBL] [Abstract][Full Text] [Related]
8. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
Rustin G; Vergote I; Micha JP; Duska LR; Reed N; Bendell J; Spitz D; Dark G; Hoch U; Tagliaferri M; Hannah AL; Garcia AA
Gynecol Oncol; 2017 Nov; 147(2):276-282. PubMed ID: 28935273
[TBL] [Abstract][Full Text] [Related]
10. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
Bardhi E; Marchetti C; Scopelliti A; Musacchio L; Tomao F; Schiavi M; Carraro C; Palaia I; Monti M; Muzii L; Benedetti Panici P
Expert Opin Investig Drugs; 2019 Aug; 28(8):667-673. PubMed ID: 31353973
[No Abstract] [Full Text] [Related]
11. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
12. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
[TBL] [Abstract][Full Text] [Related]
13. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Lenz HJ; Philip P; Saunders M; Kolevska T; Mukherjee K; Samuel L; Bondarde S; Dobbs T; Tagliaferri M; Hoch U; Hannah AL; Berkowitz M
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1161-1169. PubMed ID: 29043412
[TBL] [Abstract][Full Text] [Related]
14. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Diéras V; Müller V; Du Y; Currie SL; Hoch U; Tagliaferri M; Hannah AL; Cortés J;
JAMA Oncol; 2022 Jul; 8(7):1047-1052. PubMed ID: 35552364
[TBL] [Abstract][Full Text] [Related]
15. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
Tripathy D; Tolaney SM; Seidman AD; Anders CK; Ibrahim N; Rugo HS; Twelves C; Dieras V; Müller V; Tagliaferri M; Hannah AL; Cortés J
Future Oncol; 2019 Jul; 15(19):2211-2225. PubMed ID: 31074641
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.
Kümler I; Sørensen PG; Palshof J; Høgdall E; Skovrider-Ruminski W; Theile S; Fullerton A; Nielsen PG; Jensen BV; Nielsen DL
Cancer Chemother Pharmacol; 2019 Jan; 83(1):169-178. PubMed ID: 30406838
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
[TBL] [Abstract][Full Text] [Related]
18. Etirinotecan pegol: an option for late-stage breast cancer?
Nielsen DL; Brünner N
Lancet Oncol; 2013 Nov; 14(12):1149-51. PubMed ID: 24095297
[No Abstract] [Full Text] [Related]
19. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.
Anthoney DA; Naik J; Macpherson IR; Crawford D; Hartley JM; Hartley JA; Saito T; Abe M; Jones K; Miwa M; Twelves C; Evans TR
BMC Cancer; 2012 Nov; 12():536. PubMed ID: 23170896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
